Key result
Angiotensin-converting enzyme inhibitor therapy demonstrates benefit in managing anthracycline-induced cardiomyopathy, while the preventive use of antioxidants requires further investigation.
ACE inhibitors are recommended for early intervention in anthracycline-induced cardiomyopathy, while the preventive role of antioxidants remains to be fully established.
ACE inhibitors may warrant consideration in anthracycline cardiomyopathy management; leaves open the preventive role of antioxidants for prospective trials.
Anthracycline cardiomyopathy is less frequently encountered nowadays, due to the well-recognised dose limitations and cardiac monitoring protocols used by chemotherapy centres. However, it is a condition that will persist due to the sensitivity of some patients to these drugs and the necessity for large doses to be used for certain individuals. We have demonstrated the benefit of angiotensin-converting enzyme inhibitor therapy and would consider introducing these compounds at the earliest opportunity. The use of probucol and vitamins as antioxidants capable of preventing the onset of cardiomyopathy in humans appears to require further investigation but may significantly reduce the incidence of this condition in the future.
No takes yet. Share an insight, caveat, or question.
Fisher et al. (1999) conducted a review in Anthracycline-induced cardiomyopathy. Angiotensin-converting enzyme inhibitors, probucol, and vitamins was evaluated. Angiotensin-converting enzyme inhibitor therapy demonstrates benefit in managing anthracycline-induced cardiomyopathy, while the preventive use of antioxidants requires further investigation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: